Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Interest & Investment Income: 2016-2024

Historic Interest & Investment Income for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to $32.4 million.

  • Autolus Therapeutics' Interest & Investment Income fell 47.33% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.2 million, marking a year-over-year decrease of 16.90%. This contributed to the annual value of $32.4 million for FY2024, which is 139.58% up from last year.
  • According to the latest figures from FY2024, Autolus Therapeutics' Interest & Investment Income is $32.4 million, which was up 139.58% from $13.5 million recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Interest & Investment Income peaked at $32.4 million during FY2024, and registered a low of -$535,489 during FY2020.
  • Moreover, its 3-year median value for Interest & Investment Income was $13.5 million (2023), whereas its average is $15.9 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 116.50% in 2020, then spiked by 690.69% in 2023.
  • Over the past 5 years, Autolus Therapeutics' Interest & Investment Income (Yearly) stood at -$535,489 in 2020, then spiked by 148.93% to $262,000 in 2021, then skyrocketed by 551.91% to $1.7 million in 2022, then spiked by 690.69% to $13.5 million in 2023, then soared by 139.58% to $32.4 million in 2024.